Physician profile
Viola Kanevsky
NPI 1417976598
$4,766.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $1,187 · 2021: $1,502 · 2022: $1,115 · 2023: $219 · 2024: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $2,083.29 | 2020-2024 | |
| Johnson & Johnson Vision Care, INC. | $562.07 | 2022-2024 | Acuvue |
| Sight Sciences, INC. | $290.34 | 2022 | |
| Coopervision INC. | $254.13 | 2019-2021 | |
| Dompe US, INC. | $248.89 | 2022-2023 | Oxervate |
| Glaukos Corporation | $230.13 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $202.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $186.48 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $184.08 | 2022-2023 | Infuse, Lotemax Sm, Vyzulta |
| Eyevance Pharmaceuticals LLC | $150.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Allergan, INC. | $87.42 | 2020-2021 | |
| Shire North American Group INC | $65.96 | 2019 | |
| Alcon Vision LLC | $56.66 | 2019 | |
| Abbvie INC. | $47.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viola Kanevsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.